Abbott Laboratories (ABT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
October 2018
157
About the Report
About the Report
Summary
Abbott Laboratories (Abbott) develops, manufactures, and sells a diversified range of healthcare products including drugs, diagnostics, branded generics, and vascular and nutritional products. The company's products comprise specialized medicines; medical diagnostic instruments and tests; minimally invasive surgical devices; nutritional supplements for infants, children and adults; and products for veterinary care. It has research and development, manufacturing and administrative facilities across the world. The company markets its products in North America, Latin America, the Caribbean, the Middle East, Europe, Asia-Pacific and Africa. Abbott is headquartered in Abbott Park, Illinois, the US.
Abbott Laboratories (ABT)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Abbott Laboratories, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Abbott Laboratories, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Abbott Laboratories, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Abbott Laboratories, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Abbott Laboratories, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Abbott Laboratories, Medical Devices Deals, 2012 to YTD 2018 13
Abbott Laboratories, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Abbott Laboratories, Pharmaceuticals & Healthcare, Deal Details 18
Asset Purchase 18
Abbott Labs And Organon BioSciences Plan To Acquire Certain Pharma Assets From Johnson & Johnson 18
Thoratec Acquires DuraHeart II Ventricular Assist System From Terumo For USD 56.5 Million 20
Abbott Labs Acquires AP214 From Action Pharma For USD 110 Million 22
Venture Financing 23
NeuroGenetic Pharma Raises USD 0.2 Million In Venture Financing 23
NeuroGenetic Pharma Secures Investment In Venture Financing 24
Private Equity 25
Sanofi Plans to Sell Portfolio of Mature Drugs for USD8.6 Billion 25
Partnerships 27
BioPorto Diagnostics Enters Into Licensing Agreement With Abbott Labs 27
Cipher Pharma and Italmex Enter into Distribution Agreement 28
Veropharm Enters into Agreement with Bion 29
Hennepin County Medical Center, University of Minnesota and Abbott Labs Enter into Agreement 30
AstraZeneca Enters into Co-Development Agreement with Abbott Labs 31
ALK-Abello Expands Partnership with Abbott Labs 32
Advanced Biological Enters into Agreement with Abbott for HIV Genotyping Data Analysis Software 33
Abbott Labs Enters into Co-Development Agreement with US Department of Defense 34
Abbott Molecular Enters into Co-Development Agreement with Biocartis 35
Abbott Enters Into Distribution Agreement With WhanIn For Depakote 36
Astellas Pharma Global Development Enters Into Co-Development Agreement With Abbott Labs For Cytomegalovirus Vaccine Trial 37
ChemDiv Research Institute Expands Co-Development Agreement with Abbott Labs 38
biOasis Technologies Enters Into Research Agreement With Abbott Labs 39
Abbott India Enters Into Joint Venture Agreement With Syngene International 40
Abbott Enters Into Co-Development Agreement With Galapagos For Autoimmune Disease Drug 41
DNDi Enters Into Co-Development Agreement With Abbott Labs For Neglected Tropical Diseases 43
Licensing Agreements 44
Abbott Molecular Enters into Licensing Agreement with Institut Curie 44
Novartis Enters into Licensing Agreement with Abbott Vascular for Everolimus 45
Sepstone Enters into Licensing Agreement with Abbott Labs 47
Zealand Pharma Enters Into Licensing Agreement With Abbott Labs For AP214 48
Apricus Biosciences Enters Into Licensing Agreement With Abbott Labs For Vitaros 49
Abbott India Enters into Licensing Agreement with Bharat Biotech 50
Equity Offering 51
Abbott Labs Plans to Raise USD3 Billion in Public Offering of Shares 51
Abbott Sells stock of Mylan for USD2.29 Billion 52
AbbVie Spin Out from Abbott Laboratories 53
Debt Offering 54
Abbott Labs Raises USD1.33 Billion in Public Offering of 1.5% Bonds Due 2026 54
Abbott Labs Raises USD1.33 Billion in Public Offering of 0.875% Bonds Due 2023 55
Abbott Labs Raises USD1.33 Billion in Public Offering of Bonds Due 2020 56
Abbott Labs Raises USD3 Billion in Public Offering of 3.75% Notes due 2026 57
Abbott Labs Raises USD1.5 Billion in Public Offering of 3.4% Notes Due 2023 59
Abbott Labs Raises USD1.65 Billion in Public Offering of 4.75% Notes due 2036 61
Abbott Labs Raises USD2.85 Billion in Public Offering of 2.9% Notes due 2021 63
Abbott Labs Raises USD2.85 Billion in Public Offering of 2.35% Notes due 2019 65
Abbott Labs Raises USD3.25 Billion in Public Offering of 4.9% Notes due 2046 67
Abbott Labs Raises USD2.5 Billion in Public Offering of 2% Notes Due 2020 69
Abbott Labs Raises USD750 Million in Public Offering of 2.55% Notes Due 2022 70
Abbott Labs Raises USD1 Billion in Public Offering of 2.55% Notes Due 2025 71
Alere Completes Private Placement Of Notes Due 2020 For USD 425 Million 72
Alere Completes Private Placement Of Notes Due 2018 For USD 450 Million 73
CFR International Completes Public Offering Of Notes For USD 300 Million 74
Abbott Completes Private Placement Of Notes Due 2015 For USD 500 Million 75
Abbott Completes Private Placement Of Notes Due 2042 For USD 2.6 Billion 76
Abbott Completes Private Placement Of Notes Due 2015 For USD 3.5 Billion 77
Abbott Completes Private Placement Of Notes Due 2017 For USD 4 Billion 79
Abbott Completes Private Placement Of Notes Due 2018 For USD 1 Billion 80
Abbott Completes Private Placement Of Notes Due 2022 For USD 3.1 Billion 81
Asset Transactions 82
Corona Remedies Acquires Obimet and Thyrocab from Abbott 82
Abbott India May Sell Low-End Brands 83
Mylan Acquires Branded Generics Business of Abbott for USD5.3 Billion 84
Abbott Labs Rumored To Divest Part Of Generic Drug Business 86
Acquisition 87
Abbott Labs Acquires Alere 87
Johnson & Johnson Acquires Abbott Medical Optics from Abbott Laboratories for USD4.32 Billion 90
Optum Acquires Alere Health for USD600 Million 91
Persivia Acquires Alere Analytics 92
Abbott Labs Acquires Veropharm from Roman Avdeev for up to USD415 Million 93
Abbott Labs Acquires CFR Pharma for USD2.9 Billion 94
Jude Medical Completes Acquisition of NeuroTherm for USD200 Million 96
GardenHills Completes Acquisition Of Additional 29.09% Interest In Veropharm For USD 86.3 Million 97
Arriva Medical Acquires Simplex Healthcare 99
GardenHills To Acquire 47.99% Stake In Verofarm 100
Pfizer, Novartis And Abbott Labs Reportedly Plan To Bid For Ache Labs 101
Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 103
CFR Pharma Acquires Laboratorio Franco Colombiano Lafrancol And Its Subsidiaries 105
AFK Sistema Plans To Acquire 51.8% Stake In Veropharm From Aptechnaya set' 36,6 106
Russian Authorities Reject Abbott's Bid To Acquire 62.5% Stake In Petrovax Pharm, Drug Manufacturer 107
CFR Pharma Acquires 50% Stake In Stellence For USD 21 Million 109
STARLIMS Technologies Acquires Distribution Partners 110
CFR Pharma Acquires 41.88% Stake In Domesco Medical For USD 14.4 Million 111
Abbott Laboratories-Key Competitors 112
Abbott Laboratories-Key Employees 113
Abbott Laboratories-Locations And Subsidiaries 115
Head Office 115
Other Locations & Subsidiaries 115
Recent Developments 133
Financial Announcements 133
Jul 18, 2018: Abbott reports second-Quarter 2018 Results 133
Apr 18, 2018: Abbott Reports First-Quarter 2018 Results 136
Jan 24, 2018: Abbott Reports Fourth-Quarter 2017 Results 139
Oct 18, 2017: Abbott Reports Third-Quarter 2017 Results 142
Jul 20, 2017: Abbott Reports Second-Quarter 2017 Results 145
Apr 19, 2017: Abbott Reports First-Quarter 2017 Results 147
Corporate Communications 149
Sep 22, 2017: Abbott and the Abbott Fund Provide USD 2 Million in Additional Relief to Help Families Affected by Hurricane Maria and the Earthquake in Central Mexico 149
Sep 18, 2017: Abbott and the Abbott Fund Expand Support for Hurricane Relief With USD 1 Million to Help Families Affected by Hurricane Irma 150
Aug 29, 2017: Abbott and the Abbott Fund Donate USD 1 Million to Support Hurricane Harvey Relief Efforts 151
Government and Public Interest 152
Jun 25, 2018: Two diabetes medications don't slow progression of type 2 diabetes in youth 152
Feb 23, 2017: First Ever Cannabis-Based ETF to Include PharmaCyte Biotech, Abbott Laboratories, and GW Pharmaceuticals 154
Product News 155
Apr 18, 2018: Abbott to produce new infertility drug in Russia 155
Other Significant Developments 156
Jun 19, 2018: ClearStar Expands Medical Testing with Abbott Laboratories Integration 156
Appendix 157
Methodology 157
About GlobalData 157
Contact Us 157
Disclaimer 157
List of Figure
List of Figures
Abbott Laboratories, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Abbott Laboratories, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Abbott Laboratories, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Abbott Laboratories, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Abbott Laboratories, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Abbott Laboratories, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
Abbott Laboratories, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Abbott Laboratories, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Abbott Laboratories, Medical Devices Deals, 2012 to YTD 2018 13
List of Table
List of Tables
Abbott Laboratories, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Abbott Laboratories, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Abbott Laboratories, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Abbott Laboratories, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Abbott Laboratories, Deals By Therapy Area, 2012 to YTD 2018 11
Abbott Laboratories, Medical Devices Deals, 2012 to YTD 2018 13
Abbott Laboratories, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Abbott Labs And Organon BioSciences Plan To Acquire Certain Pharma Assets From Johnson & Johnson 18
Thoratec Acquires DuraHeart II Ventricular Assist System From Terumo For USD 56.5 Million 20
Abbott Labs Acquires AP214 From Action Pharma For USD 110 Million 22
NeuroGenetic Pharma Raises USD 0.2 Million In Venture Financing 23
NeuroGenetic Pharma Secures Investment In Venture Financing 24
Sanofi Plans to Sell Portfolio of Mature Drugs for USD8.6 Billion 25
BioPorto Diagnostics Enters Into Licensing Agreement With Abbott Labs 27
Cipher Pharma and Italmex Enter into Distribution Agreement 28
Veropharm Enters into Agreement with Bion 29
Hennepin County Medical Center, University of Minnesota and Abbott Labs Enter into Agreement 30
AstraZeneca Enters into Co-Development Agreement with Abbott Labs 31
ALK-Abello Expands Partnership with Abbott Labs 32
Advanced Biological Enters into Agreement with Abbott for HIV Genotyping Data Analysis Software 33
Abbott Labs Enters into Co-Development Agreement with US Department of Defense 34
Abbott Molecular Enters into Co-Development Agreement with Biocartis 35
Abbott Enters Into Distribution Agreement With WhanIn For Depakote 36
Astellas Pharma Global Development Enters Into Co-Development Agreement With Abbott Labs For Cytomegalovirus Vaccine Trial 37
ChemDiv Research Institute Expands Co-Development Agreement with Abbott Labs 38
biOasis Technologies Enters Into Research Agreement With Abbott Labs 39
Abbott India Enters Into Joint Venture Agreement With Syngene International 40
Abbott Enters Into Co-Development Agreement With Galapagos For Autoimmune Disease Drug 41
DNDi Enters Into Co-Development Agreement With Abbott Labs For Neglected Tropical Diseases 43
Abbott Molecular Enters into Licensing Agreement with Institut Curie 44
Novartis Enters into Licensing Agreement with Abbott Vascular for Everolimus 45
Sepstone Enters into Licensing Agreement with Abbott Labs 47
Zealand Pharma Enters Into Licensing Agreement With Abbott Labs For AP214 48
Apricus Biosciences Enters Into Licensing Agreement With Abbott Labs For Vitaros 49
Abbott India Enters into Licensing Agreement with Bharat Biotech 50
Abbott Labs Plans to Raise USD3 Billion in Public Offering of Shares 51
Abbott Sells stock of Mylan for USD2.29 Billion 52
AbbVie Spin Out from Abbott Laboratories 53
Abbott Labs Raises USD1.33 Billion in Public Offering of 1.5% Bonds Due 2026 54
Abbott Labs Raises USD1.33 Billion in Public Offering of 0.875% Bonds Due 2023 55
Abbott Labs Raises USD1.33 Billion in Public Offering of Bonds Due 2020 56
Abbott Labs Raises USD3 Billion in Public Offering of 3.75% Notes due 2026 57
Abbott Labs Raises USD1.5 Billion in Public Offering of 3.4% Notes Due 2023 59
Abbott Labs Raises USD1.65 Billion in Public Offering of 4.75% Notes due 2036 61
Abbott Labs Raises USD2.85 Billion in Public Offering of 2.9% Notes due 2021 63
Abbott Labs Raises USD2.85 Billion in Public Offering of 2.35% Notes due 2019 65
Abbott Labs Raises USD3.25 Billion in Public Offering of 4.9% Notes due 2046 67
Abbott Labs Raises USD2.5 Billion in Public Offering of 2% Notes Due 2020 69
Abbott Labs Raises USD750 Million in Public Offering of 2.55% Notes Due 2022 70
Abbott Labs Raises USD1 Billion in Public Offering of 2.55% Notes Due 2025 71
Alere Completes Private Placement Of Notes Due 2020 For USD 425 Million 72
Alere Completes Private Placement Of Notes Due 2018 For USD 450 Million 73
CFR International Completes Public Offering Of Notes For USD 300 Million 74
Abbott Completes Private Placement Of Notes Due 2015 For USD 500 Million 75
Abbott Completes Private Placement Of Notes Due 2042 For USD 2.6 Billion 76
Abbott Completes Private Placement Of Notes Due 2015 For USD 3.5 Billion 77
Abbott Completes Private Placement Of Notes Due 2017 For USD 4 Billion 79
Abbott Completes Private Placement Of Notes Due 2018 For USD 1 Billion 80
Abbott Completes Private Placement Of Notes Due 2022 For USD 3.1 Billion 81
Corona Remedies Acquires Obimet and Thyrocab from Abbott 82
Abbott India May Sell Low-End Brands 83
Mylan Acquires Branded Generics Business of Abbott for USD5.3 Billion 84
Abbott Labs Rumored To Divest Part Of Generic Drug Business 86
Abbott Labs Acquires Alere 87
Johnson & Johnson Acquires Abbott Medical Optics from Abbott Laboratories for USD4.32 Billion 90
Optum Acquires Alere Health for USD600 Million 91
Persivia Acquires Alere Analytics 92
Abbott Labs Acquires Veropharm from Roman Avdeev for up to USD415 Million 93
Abbott Labs Acquires CFR Pharma for USD2.9 Billion 94
Jude Medical Completes Acquisition of NeuroTherm for USD200 Million 96
GardenHills Completes Acquisition Of Additional 29.09% Interest In Veropharm For USD 86.3 Million 97
Arriva Medical Acquires Simplex Healthcare 99
GardenHills To Acquire 47.99% Stake In Verofarm 100
Pfizer, Novartis And Abbott Labs Reportedly Plan To Bid For Ache Labs 101
Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 103
CFR Pharma Acquires Laboratorio Franco Colombiano Lafrancol And Its Subsidiaries 105
AFK Sistema Plans To Acquire 51.8% Stake In Veropharm From Aptechnaya set' 36,6 106
Russian Authorities Reject Abbott's Bid To Acquire 62.5% Stake In Petrovax Pharm, Drug Manufacturer 107
CFR Pharma Acquires 50% Stake In Stellence For USD 21 Million 109
STARLIMS Technologies Acquires Distribution Partners 110
CFR Pharma Acquires 41.88% Stake In Domesco Medical For USD 14.4 Million 111
Abbott Laboratories, Key Competitors 112
Abbott Laboratories, Key Employees 113
Abbott Laboratories, Other Locations 115
Abbott Laboratories, Subsidiaries 115
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.